News & Media

Metamark Genetics, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses novel molecular diagnostic technologies, has issued final local coverage determination (LCD) for ProMark®, the first and only proteomic prognostic test for early-stage prostate cancer.

Metamark Genetics, Inc., a leader in providing critical diagnostic and prognostic information to enable more informed treatment decisions for urological cancer, today announced that effective May 25, 2016, the Company has signed an agreement with Anthem Blue Cross Blue Shield of Georgia.

Metamark, a leader in commercializing high-value urologic oncology products, today announced that ProMark®, the first and only protein-based prognostic test for early-stage prostate cancer, has been included in the 2016 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines.

Data published in The Oncologist support use of ProMark® as a likely cost-effective addition to current guidelines for management of Gleason 3+3 and 3+4 early-stage prostate cancer.

Metamark announced today that results of its clinical validation study for the ProMark™ prostate cancer test were published online in Clinical Cancer Research.

Metamark announced today that it has signed an agreement with Highmark Blue Shield to provide its members with in-network access to Metamark’s comprehensive suite of urology specialized diagnostic offerings.

Cambridge Laboratory Will Serve as Primary Location for Processing ProMark™, the Company’s Newly-Launched Prostate Cancer Prognostic Test

Metamark announced today the nationwide availability of ProMark™, the first-of-its-kind protein-based biopsy test designed to improve the accuracy of prognosis for men diagnosed with prostate cancer.

Metamark Genetics, Inc. today announced that it has initiated clinical use of the company’s ProMark™ prognostic test to help guide the medical management of patients with early-stage prostate cancer.

Metamark today announced that its Chief Scientific Officer, Peter Blume-Jensen, M.D., Ph.D., will be joining a targeted therapeutics startup, and will continue working for Metamark as a member of the company’s Scientific Advisory Board and as a consultant.

ProMark™ has Potential to Transform Prostate Cancer Care by Aiding Doctors and Patients with Appropriate Treatment Assessment

Metamark Genetics, Inc. today announced that its Cambridge, Mass. laboratory has been licensed for the highest level of clinical testing in the use of ProMark™, the company's prognostic assay to guide the medical management of patients with prostate cancer.